Dernières nouvelles concernant le Syndrome Prader-Willi
-
Aardvark Tanks After Pausing Prader-Willi Study on ‘Surprise’ Safety Signals - BioSpace
Mon, 02 Mar 2026 14:46:43 GMT
-
Safety concerns spur Aardvark to halt key Prader-Willi drug trial - BioPharma Dive
Mon, 02 Mar 2026 14:22:50 GMT
-
GLP-1 weight-loss drugs work in rare genetic obesity, study finds - The South First
Sun, 01 Mar 2026 01:30:17 GMT
-
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
Sat, 28 Feb 2026 13:03:13 GMT
-
Aardvark Therapeutics announces voluntary pause of phase 3 HERO trial in Prader-Willi syndrome - marketscreener.com
Fri, 27 Feb 2026 21:35:20 GMT
-
Cardiac findings prompt pause of Prader-Willi hunger drug trial - Stock Titan
Fri, 27 Feb 2026 21:05:00 GMT
-
Support the HERO Clinical Trial for Prader-Willi Syndrome - 9News
Thu, 26 Feb 2026 17:21:00 GMT
-
I’m hopeful a new treatment will benefit my son with Prader-Willi syndrome - Prader-Willi Syndrome News
Mon, 23 Feb 2026 18:41:15 GMT
-
Clinical Trial Aims to Improve Daily Life for People with Prader-Willi Syndrome and Their Families - InsideNoVa.com
Mon, 23 Feb 2026 16:05:00 GMT
-
Death of disabled man who had dream to break record was 'avoidable' - Health and Disability Commission - RNZ
Sun, 25 Jan 2026 08:00:00 GMT
Copyrights :
Feed from : Copyright © 2026 Google. All rights reserved. This XML feed is made available solely for the purpose of rendering Google News results within a personal feed reader for personal, non-commercial use. Any other use of the feed is expressly prohibited. By accessing this feed or using these results in any manner whatsoever, you agree to be bound by the foregoing restrictions.
Module from : ©2013 CAPRICE - IT Services. Tous droits réservés.
Feed from : Copyright © 2026 Google. All rights reserved. This XML feed is made available solely for the purpose of rendering Google News results within a personal feed reader for personal, non-commercial use. Any other use of the feed is expressly prohibited. By accessing this feed or using these results in any manner whatsoever, you agree to be bound by the foregoing restrictions.
Module from : ©2013 CAPRICE - IT Services. Tous droits réservés.